Goldman Sachs
INO icon

Goldman Sachs’s Inovio Pharmaceuticals INO Stock Holding History

Goldman Sachs’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,683
Closed -$128K – 6495
2017
Q3 		$128K Hold
1,683
– – ﹤0.01% 5964
2017
Q2 		$158K Buy
+1,683
New +$144K ﹤0.01% 5922
2016
Q1 		– Sell
-28,533
Closed -$2.3M – 7186
2015
Q4 		$2.3M Hold
28,533
– – ﹤0.01% 3504
2015
Q3 		$1.98M Buy
+28,533
New +$2.49M ﹤0.01% 3806

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's INO Position: Q2 2026 in Review

Goldman Sachs increased its Inovio Pharmaceuticals (INO) stake by 110% in Q2 2026, buying an estimated $58.1K and bringing the position to 93,720 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #6328.

Goldman Sachs first reported a position in INO in Q4 2013 and has held it in 50 quarters since. The position peaked at $14.4M in Q2 2020. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Goldman Sachs held 93,720 shares of Inovio Pharmaceuticals worth $103K as of Q2 2026.
  • Goldman Sachs bought 48,996 Inovio Pharmaceuticals shares in Q2 2026, an estimated $58.1K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6328 holding.
  • Goldman Sachs first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Goldman Sachs's Inovio Pharmaceuticals position peaked at $14.4M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.